Difference between revisions of "HAEM5:Volunteer Assignments and Opportunities"
Jump to navigation
Jump to search
[unchecked revision] | [unchecked revision] |
Line 5: | Line 5: | ||
!Correlated Prior Disease Name (4th Edition) | !Correlated Prior Disease Name (4th Edition) | ||
!Correlated Prior Author (4th Edition) | !Correlated Prior Author (4th Edition) | ||
+ | !Content Status (4th Edition)(Pending or Complete) | ||
!Date of Last Editor Review (4th Edition) | !Date of Last Editor Review (4th Edition) | ||
!Notes (4th Edition) | !Notes (4th Edition) | ||
Line 13: | Line 14: | ||
| | | | ||
----<br /> | ----<br /> | ||
+ | | | ||
| | | | ||
| | | | ||
Line 26: | Line 28: | ||
|- | |- | ||
|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| || | |Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| || | ||
+ | |NEW DISEASE | ||
+ | |NEW (No Prior) | ||
+ | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
− | |||
− | |||
|- | |- | ||
|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR|| || | |Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR|| || | ||
+ | |NEW DISEASE | ||
+ | |NEW (No Prior) | ||
+ | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
− | |||
− | |||
|- | |- | ||
|Chronic myeloid leukaemia||Disease|| || || || || ||FQR|| || | |Chronic myeloid leukaemia||Disease|| || || || || ||FQR|| || | ||
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive | |Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive | ||
|Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | |Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | ||
+ | | | ||
|Date page was created | |Date page was created | ||
| | | | ||
Line 46: | Line 51: | ||
|Chronic Neutrophilic Leukemia (CNL) | |Chronic Neutrophilic Leukemia (CNL) | ||
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally | |Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally | ||
+ | | | ||
|Date page was created | |Date page was created | ||
| | | | ||
Line 52: | Line 58: | ||
|Chronic Eosinophilic Leukemia, Not Otherwise Specified | |Chronic Eosinophilic Leukemia, Not Otherwise Specified | ||
|Chelsea D. Kramish; Daynna J.Wolff | |Chelsea D. Kramish; Daynna J.Wolff | ||
+ | | | ||
| | | | ||
| | | | ||
Line 58: | Line 65: | ||
|Polycythemia Vera (PV) | |Polycythemia Vera (PV) | ||
|Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center | |Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center | ||
+ | | | ||
| | | | ||
| | | | ||
|- | |- | ||
− | |Essential thrombocythaemia||Disease|| | + | |Essential thrombocythaemia||Disease|| || || || || ||FQR|| || |
|Essential Thrombocythemia (ET) | |Essential Thrombocythemia (ET) | ||
+ | |Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | ||
| | | | ||
| | | | ||
Line 68: | Line 77: | ||
|- | |- | ||
|Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR|| || | |Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 74: | Line 84: | ||
|- | |- | ||
|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology Associate Director | Division of Molecular Pathology, Genetics and Genomics Duke University Health System Clinical Laboratories|| || || || ||FQR|| || | |Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology Associate Director | Division of Molecular Pathology, Genetics and Genomics Duke University Health System Clinical Laboratories|| || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 80: | Line 91: | ||
|- | |- | ||
|Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR|| || | |Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 86: | Line 98: | ||
|- | |- | ||
|Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR|| || | |Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 92: | Line 105: | ||
|- | |- | ||
|Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR|| || | |Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 98: | Line 112: | ||
|- | |- | ||
|Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR|| || | |Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 104: | Line 119: | ||
|- | |- | ||
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| || | |Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 110: | Line 126: | ||
|- | |- | ||
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| || | |Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 116: | Line 133: | ||
|- | |- | ||
|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR|| || | |Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 122: | Line 140: | ||
|- | |- | ||
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| || | |Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 128: | Line 147: | ||
|- | |- | ||
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| || | |Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 134: | Line 154: | ||
|- | |- | ||
|Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| || | |Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 140: | Line 161: | ||
|- | |- | ||
|Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| || | |Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 146: | Line 168: | ||
|- | |- | ||
|Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| || | |Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 152: | Line 175: | ||
|- | |- | ||
|Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| || | |Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 158: | Line 182: | ||
|- | |- | ||
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| || | |Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 164: | Line 189: | ||
|- | |- | ||
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR|| || | |Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 170: | Line 196: | ||
|- | |- | ||
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia|| || || || ||FQR|| || | |Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia|| || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 176: | Line 203: | ||
|- | |- | ||
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR|| || | |Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 182: | Line 210: | ||
|- | |- | ||
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR|| || | |Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 188: | Line 217: | ||
|- | |- | ||
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR|| || | |Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 194: | Line 224: | ||
|- | |- | ||
|Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR|| || | |Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 200: | Line 231: | ||
|- | |- | ||
|Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR|| || | |Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 206: | Line 238: | ||
|- | |- | ||
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR|| || | |Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 212: | Line 245: | ||
|- | |- | ||
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| || | |Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 225: | Line 259: | ||
| | | | ||
|Jennelle Hodge (JH)/ Malini Sathanoori (MS) | |Jennelle Hodge (JH)/ Malini Sathanoori (MS) | ||
+ | | | ||
| | | | ||
| | | | ||
Line 240: | Line 275: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 255: | Line 291: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 270: | Line 307: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 285: | Line 323: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 300: | Line 339: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 315: | Line 355: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 330: | Line 371: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 345: | Line 387: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 360: | Line 403: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 375: | Line 419: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 390: | Line 435: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 405: | Line 451: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 420: | Line 467: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 435: | Line 483: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 450: | Line 499: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 465: | Line 515: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 480: | Line 531: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 495: | Line 547: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 510: | Line 563: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 525: | Line 579: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 540: | Line 595: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 555: | Line 611: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 570: | Line 627: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 585: | Line 643: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 600: | Line 659: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 615: | Line 675: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 630: | Line 691: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 645: | Line 707: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 660: | Line 723: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 675: | Line 739: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 690: | Line 755: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 705: | Line 771: | ||
| | | | ||
|JH_MS | |JH_MS | ||
+ | | | ||
| | | | ||
| | | | ||
Line 717: | Line 784: | ||
| | | | ||
----<br /> | ----<br /> | ||
+ | | | ||
| | | | ||
| | | | ||
Line 737: | Line 805: | ||
| | | | ||
|Greg Corboy (GC) | |Greg Corboy (GC) | ||
+ | | | ||
| | | | ||
| | | | ||
Line 752: | Line 821: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 767: | Line 837: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 782: | Line 853: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 797: | Line 869: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 812: | Line 885: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 827: | Line 901: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 842: | Line 917: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 857: | Line 933: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 872: | Line 949: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 887: | Line 965: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 899: | Line 978: | ||
| | | | ||
----<br /> | ----<br /> | ||
+ | | | ||
| | | | ||
| | | | ||
Line 919: | Line 999: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 934: | Line 1,015: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 949: | Line 1,031: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 964: | Line 1,047: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 979: | Line 1,063: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 994: | Line 1,079: | ||
| | | | ||
|Holli Drendel (HD) | |Holli Drendel (HD) | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,009: | Line 1,095: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,024: | Line 1,111: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,039: | Line 1,127: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,054: | Line 1,143: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,069: | Line 1,159: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,084: | Line 1,175: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,099: | Line 1,191: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,114: | Line 1,207: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,129: | Line 1,223: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,144: | Line 1,239: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,159: | Line 1,255: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,174: | Line 1,271: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,189: | Line 1,287: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,198: | Line 1,297: | ||
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG) | |Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG) | ||
| || | | || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,204: | Line 1,304: | ||
|- | |- | ||
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD|| || || || ||SG|| || | |Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD|| || || || ||SG|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,210: | Line 1,311: | ||
|- | |- | ||
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| || | |Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,216: | Line 1,318: | ||
|- | |- | ||
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| || | |Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,222: | Line 1,325: | ||
|- | |- | ||
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| || | |Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,235: | Line 1,339: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,250: | Line 1,355: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,265: | Line 1,371: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,280: | Line 1,387: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,295: | Line 1,403: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,310: | Line 1,419: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,325: | Line 1,435: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,340: | Line 1,451: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,355: | Line 1,467: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,370: | Line 1,483: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,385: | Line 1,499: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,400: | Line 1,515: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,415: | Line 1,531: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,430: | Line 1,547: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,445: | Line 1,563: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,453: | Line 1,572: | ||
|- | |- | ||
|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| || | |Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,459: | Line 1,579: | ||
|- | |- | ||
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| || | |T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,465: | Line 1,586: | ||
|- | |- | ||
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| || | |Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,471: | Line 1,593: | ||
|- | |- | ||
|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| || | |ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,477: | Line 1,600: | ||
|- | |- | ||
|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| || | |Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,483: | Line 1,607: | ||
|- | |- | ||
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| || | |High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,489: | Line 1,614: | ||
|- | |- | ||
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| || | |Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,495: | Line 1,621: | ||
|- | |- | ||
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| || | |EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,501: | Line 1,628: | ||
|- | |- | ||
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| || | |Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,507: | Line 1,635: | ||
|- | |- | ||
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| || | |Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,513: | Line 1,642: | ||
|- | |- | ||
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| || | |Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,519: | Line 1,649: | ||
|- | |- | ||
|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| || | |Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,525: | Line 1,656: | ||
|- | |- | ||
|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| || | |Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,531: | Line 1,663: | ||
|- | |- | ||
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| || | |Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,537: | Line 1,670: | ||
|- | |- | ||
|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| || | |Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,543: | Line 1,677: | ||
|- | |- | ||
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| || | |Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,549: | Line 1,684: | ||
|- | |- | ||
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| || | |Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,555: | Line 1,691: | ||
|- | |- | ||
|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| || | |High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,561: | Line 1,698: | ||
|- | |- | ||
|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| || | |Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,567: | Line 1,705: | ||
|- | |- | ||
|Primary effusion lymphoma||Disease|| || || || || ||GC|| || | |Primary effusion lymphoma||Disease|| || || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,573: | Line 1,712: | ||
|- | |- | ||
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| || | |KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,579: | Line 1,719: | ||
|- | |- | ||
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| || | |KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,585: | Line 1,726: | ||
|- | |- | ||
|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| || | |Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,591: | Line 1,733: | ||
|- | |- | ||
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| || | |Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,597: | Line 1,740: | ||
|- | |- | ||
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| || | |EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,603: | Line 1,747: | ||
|- | |- | ||
|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| || | |Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,609: | Line 1,754: | ||
|- | |- | ||
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| || | |Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,615: | Line 1,761: | ||
|- | |- | ||
|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| || | |Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,621: | Line 1,768: | ||
|- | |- | ||
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| || | |Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,634: | Line 1,782: | ||
| | | | ||
|SG | |SG | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,642: | Line 1,791: | ||
|- | |- | ||
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| || | |IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,648: | Line 1,798: | ||
|- | |- | ||
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| || | |Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,655: | Line 1,806: | ||
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG | |Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG | ||
| || | | || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,662: | Line 1,814: | ||
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG | |Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG | ||
| || | | || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,669: | Line 1,822: | ||
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG | |Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG | ||
| || | | || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,676: | Line 1,830: | ||
|Mu heavy chain disease||Disease|| || || || || ||SG | |Mu heavy chain disease||Disease|| || || || || ||SG | ||
| || | | || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,683: | Line 1,838: | ||
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya Asst. Professor, Dept. of Pathology and Human Anatomy Technical Supervisor, Clinical Genetics Laboratory Loma Linda University, Medical Center, CA|| || || || ||SG | |Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya Asst. Professor, Dept. of Pathology and Human Anatomy Technical Supervisor, Clinical Genetics Laboratory Loma Linda University, Medical Center, CA|| || || || ||SG | ||
| || | | || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,690: | Line 1,846: | ||
|Alpha heavy chain disease||Disease|| || || || || ||SG | |Alpha heavy chain disease||Disease|| || || || || ||SG | ||
| || | | || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,697: | Line 1,854: | ||
|Plasmacytoma||Disease|| || || || || ||SG | |Plasmacytoma||Disease|| || || || || ||SG | ||
| || | | || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,704: | Line 1,862: | ||
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG | |Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG | ||
| || | | || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,711: | Line 1,870: | ||
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD|| || || || ||SG | |Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD|| || || || ||SG | ||
| || | | || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,721: | Line 1,881: | ||
| | | | ||
----<br /> | ----<br /> | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,735: | Line 1,896: | ||
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK) | |Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK) | ||
| || | | || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,741: | Line 1,903: | ||
|- | |- | ||
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| || | |Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,747: | Line 1,910: | ||
|- | |- | ||
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| || | |Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,753: | Line 1,917: | ||
|- | |- | ||
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| || | |T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,766: | Line 1,931: | ||
| | | | ||
|HD | |HD | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,781: | Line 1,947: | ||
| | | | ||
|SK | |SK | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,789: | Line 1,956: | ||
|- | |- | ||
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| || | |T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,795: | Line 1,963: | ||
|- | |- | ||
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| || | |NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,801: | Line 1,970: | ||
|- | |- | ||
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center|| || || || ||SK|| || | |Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center|| || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,807: | Line 1,977: | ||
|- | |- | ||
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| || | |Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,813: | Line 1,984: | ||
|- | |- | ||
|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| || | |Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,819: | Line 1,991: | ||
|- | |- | ||
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| || | |Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,825: | Line 1,998: | ||
|- | |- | ||
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| || | |Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,831: | Line 2,005: | ||
|- | |- | ||
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| || | |Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,837: | Line 2,012: | ||
|- | |- | ||
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| || | |Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,843: | Line 2,019: | ||
|- | |- | ||
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| || | |Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,849: | Line 2,026: | ||
|- | |- | ||
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| || | |Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,855: | Line 2,033: | ||
|- | |- | ||
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| || | |Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,861: | Line 2,040: | ||
|- | |- | ||
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| || | |Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,867: | Line 2,047: | ||
|- | |- | ||
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| || | |Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,873: | Line 2,054: | ||
|- | |- | ||
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| || | |Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,879: | Line 2,061: | ||
|- | |- | ||
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| || | |Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,885: | Line 2,068: | ||
|- | |- | ||
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| || | |Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,891: | Line 2,075: | ||
|- | |- | ||
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| || | |Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,897: | Line 2,082: | ||
|- | |- | ||
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| || | |Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,903: | Line 2,089: | ||
|- | |- | ||
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| || | |Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,909: | Line 2,096: | ||
|- | |- | ||
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| || | |ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,915: | Line 2,103: | ||
|- | |- | ||
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| || | |ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,921: | Line 2,110: | ||
|- | |- | ||
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center|| || || || ||SK|| || | |Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center|| || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,927: | Line 2,117: | ||
|- | |- | ||
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| || | |Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,933: | Line 2,124: | ||
|- | |- | ||
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| || | |Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,939: | Line 2,131: | ||
|- | |- | ||
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD|| || || || ||SK|| || | |Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD|| || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,945: | Line 2,138: | ||
|- | |- | ||
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| || | |Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,951: | Line 2,145: | ||
|- | |- | ||
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| || | |EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,957: | Line 2,152: | ||
|- | |- | ||
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| || | |Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,963: | Line 2,159: | ||
|- | |- | ||
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| || | |Severe mosquito bite allergy||Disease|| || || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,969: | Line 2,166: | ||
|- | |- | ||
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| || | |Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,975: | Line 2,173: | ||
|- | |- | ||
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| || | |Systemic chronic active EBV disease||Disease|| || || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,981: | Line 2,180: | ||
|- | |- | ||
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| || | |Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,991: | Line 2,191: | ||
| | | | ||
----<br /> | ----<br /> | ||
+ | | | ||
| | | | ||
| | | | ||
Line 2,011: | Line 2,212: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 2,026: | Line 2,228: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 2,041: | Line 2,244: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 2,056: | Line 2,260: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 2,071: | Line 2,276: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 2,086: | Line 2,292: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 2,101: | Line 2,308: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
| | | | ||
| | | | ||
Line 2,113: | Line 2,321: | ||
| | | | ||
----<br /> | ----<br /> | ||
+ | | | ||
| | | | ||
| | | | ||
Line 2,126: | Line 2,335: | ||
|- | |- | ||
|Fanconi anaemia||Disease|| || || || || ||NA|| || | |Fanconi anaemia||Disease|| || || || || ||NA|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 2,132: | Line 2,342: | ||
|- | |- | ||
|Bloom syndrome||Disease|| || || || || ||NA|| || | |Bloom syndrome||Disease|| || || || || ||NA|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 2,138: | Line 2,349: | ||
|- | |- | ||
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| || | |Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| || | ||
+ | | | ||
| | | | ||
| | | | ||
Line 2,144: | Line 2,356: | ||
|- | |- | ||
|RASopathies||Disease|| || || || || ||NA|| || | |RASopathies||Disease|| || || || || ||NA|| || | ||
+ | | | ||
| | | | ||
| | | |
Revision as of 20:35, 17 December 2023
Disease (5th Edition) | Page Type | Author (5th Edition) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Content Status (4th Edition)(Pending or Complete) | Date of Last Editor Review (4th Edition) | Notes (4th Edition) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS) |
|
|
||||||||||||
Clonal haematopoiesis | Disease | Fabiola Quintero-Rivera (FQR) | NEW DISEASE | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Clonal cytopenias of undetermined significance | Disease | FQR | NEW DISEASE | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Chronic myeloid leukaemia | Disease | FQR | Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive | Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | Date page was created | |||||||||
Chronic neutrophilic leukaemia | Disease | FQR | Chronic Neutrophilic Leukemia (CNL) | Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine **contributed equally | Date page was created | |||||||||
Chronic eosinophilic leukaemia | Disease | FQR | Chronic Eosinophilic Leukemia, Not Otherwise Specified | Chelsea D. Kramish; Daynna J.Wolff | ||||||||||
Polycythaemia vera | Disease | FQR | Polycythemia Vera (PV) | Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center | ||||||||||
Essential thrombocythaemia | Disease | FQR | Essential Thrombocythemia (ET) | Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | ||||||||||
Primary myelofibrosis | Disease | T. Niroshi Senaratne, UCLA | FQR | 8/4/2020 before submission |
||||||||||
Juvenile myelomonocytic leukaemia | Disease | Assistant Professor, Pathology Associate Director | Division of Molecular Pathology, Genetics and Genomics Duke University Health System Clinical Laboratories | FQR | PENDING importing content and reference formatting; FQR has emailed SR several times, last 4/20/22 | ||||||||||
Myeloproliferative neoplasm, NOS | Disease | Thomas Lee, MD, PhD, University of California, Los Angeles | FQR | |||||||||||
Cutaneous mastocytosis | Disease | S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD | FQR | |||||||||||
Systemic mastocytosis | Disease | Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University | FQR | |||||||||||
Mast cell sarcoma | Disease | Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL | FQR | |||||||||||
Myelodysplastic neoplasm with low blasts and 5q deletion | Disease | FQR | ||||||||||||
Myelodysplastic neoplasm with low blasts and SF3B1 mutation | Disease | FQR | ||||||||||||
Myelodysplastic neoplasm with biallelic TP53 inactivation | Disease | FQR | ||||||||||||
Myelodysplastic neoplasm with low blasts | Disease | FQR | ||||||||||||
Myelodysplastic neoplasm, hypoplastic | Disease | FQR | ||||||||||||
Myelodysplastic neoplasm with increased blasts | Disease | Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA. | FQR | |||||||||||
Childhood myelodysplastic neoplasm with low blasts | Disease | Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA. | FQR | |||||||||||
Childhood myelodysplastic neoplasm with increased blasts | Disease | Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA. | FQR | |||||||||||
Chronic myelomonocytic leukaemia | Disease | Linsheng Zhang, MD, PhD | FQR | |||||||||||
Myelodysplastic/myeloproliferative neoplasm with neutrophilia | Disease | Linsheng Zhang, MD, PhD | FQR | |||||||||||
Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis | Disease | Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine | FQR | |||||||||||
Myelodysplastic/myeloproliferative neoplasm, NOS | Disease | Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia | FQR | |||||||||||
Myeloid/lymphoid neoplasm with PDGFRA rearrangement | Disease | Jay Alden, DO | FQR | |||||||||||
Myeloid/lymphoid neoplasm with PDGFRB rearrangement | Disease | Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD | FQR | |||||||||||
Myeloid/lymphoid neoplasm with FGFR1 rearrangement | Disease | Yanna Ding, MD PhD | FQR | |||||||||||
Myeloid/lymphoid neoplasm with JAK2 rearrangement | Disease | Jessica Snider, M.D. and Daynna J. Wolff, PhD | FQR | |||||||||||
Myeloid/lymphoid neoplasm with FLT3 rearrangement | Disease | FQR | ||||||||||||
Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion | Disease | FQR | ||||||||||||
Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes | Disease | FQR | ||||||||||||
Acute promyelocytic leukaemia with PML::RARA fusion | Disease | Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D. | Jennelle Hodge (JH)/ Malini Sathanoori (MS) | |||||||||||
Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion | Disease | Christine Bryke, MD Beth Israel Deaconess Medical Center, Boston, MA |
JH_MS | |||||||||||
Acute myeloid leukaemia with CBFB::MYH11 fusion | Disease | Christine Bryke, MD Beth Israel Deaconess Medical Center, Boston, MA |
JH_MS | |||||||||||
Acute myeloid leukaemia with DEK::NUP214 fusion | Disease | JH_MS | ||||||||||||
Acute myeloid leukaemia with RBM15::MRTFA fusion | Disease | Jennelle C. Hodge, PhD, FACMG | JH_MS | |||||||||||
Acute myeloid leukaemia with BCR::ABL1 fusion | Disease | Kay Weng Choy MBBS, Monash Medical Centre | JH_MS | |||||||||||
Acute myeloid leukaemia with KMT2A rearrangement | Disease | Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D. | JH_MS | |||||||||||
Acute myeloid leukaemia with MECOM rearrangement | Disease | JH_MS | ||||||||||||
Acute myeloid leukaemia with NUP98 rearrangement | Disease | JH_MS | ||||||||||||
Acute myeloid leukaemia with NPM1 mutation | Disease | Xinjie Xu, PhD, FACMG | JH_MS | |||||||||||
Acute myeloid leukaemia with CEBPA mutation | Disease | Paul Defazio, MSc, Monash Health | JH_MS | |||||||||||
Acute myeloid leukaemia, myelodysplasia-related | Disease | Fei Yang, MD, FACMG Oregon Health & Science University, Portland, OR |
JH_MS | |||||||||||
Acute myeloid leukaemia with other defined genetic alterations | Disease | JH_MS | ||||||||||||
Acute myeloid leukaemia with minimal differentiation | Disease | Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine | JH_MS | |||||||||||
Acute myeloid leukaemia without maturation | Disease | Jennelle C. Hodge, PhD, FACMG | JH_MS | |||||||||||
Acute myeloid leukaemia with maturation | Disease | Jennelle C. Hodge, PhD, FACMG | JH_MS | |||||||||||
Acute basophilic leukaemia | Disease | Ashwini Yenamandra PhD FACMG | JH_MS | |||||||||||
Acute myelomonocytic leukaemia | Disease | Fei Yang, MD, FACMG Oregon Health & Science University, Portland, OR |
JH_MS | |||||||||||
Acute monocytic leukaemia | Disease | Fei Yang, MD, FACMG Oregon Health & Science University, Portland, OR |
JH_MS | |||||||||||
Acute erythroid leukaemia | Disease | Ashwini Yenamandra PhD FACMG | JH_MS | |||||||||||
Acute megakaryoblastic leukaemia | Disease | Fei Yang, MD, FACMG Oregon Health & Science University, Portland, OR |
JH_MS | |||||||||||
Myeloid sarcoma | Disease | Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine | JH_MS | |||||||||||
Myeloid neoplasm post cytotoxic therapy | Disease | Shawn A. Silver, DO, Shashi Shetty, Ph.D. | JH_MS | |||||||||||
Myeloid neoplasms associated with germline predisposition | Disease | JH_MS | ||||||||||||
Myeloid proliferations associated with Down syndrome | Disease | Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO | JH_MS | |||||||||||
Mixed-phenotype acute leukaemia with BCR::ABL1 fusion | Disease | Tracy Tucker, PhD, FCCMG | JH_MS | |||||||||||
Mixed-phenotype acute leukaemia with KMT2A rearrangement | Disease | Tracy Tucker, PhD, FCCMG | JH_MS | |||||||||||
Acute leukaemia of ambiguous lineage with other defined genetic alterations | Disease | JH_MS | ||||||||||||
Mixed-phenotype acute leukaemia, B/myeloid | Disease | Priyatharsini Nirmalanantham, MD and Shashi Shetty, PhD | JH_MS | |||||||||||
Mixed-phenotype acute leukaemia, T/myeloid | Disease | Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine | JH_MS | |||||||||||
Mixed-phenotype acute leukaemia, rare types | Disease | Elicia Goodale, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | JH_MS | |||||||||||
Acute leukaemia of ambiguous lineage, NOS | Disease | JH_MS | ||||||||||||
Acute undifferentiated leukaemia | Disease | Amelia Nakanishi, MD and Shashi Shetty, PhD | JH_MS | |||||||||||
CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS) |
|
|
||||||||||||
Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm | Disease | Greg Corboy (GC) | ||||||||||||
Blastic plasmacytoid dendritic cell neoplasm | Disease | Hao Liu, MD and Daynna J. Wolff, PhD | GC | |||||||||||
Langerhans cell histiocytosis | Disease | Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | GC | |||||||||||
Langerhans cell sarcoma | Disease | Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | GC | |||||||||||
Indeterminate dendritic cell tumour | Disease | GC | ||||||||||||
Interdigitating dendritic cell sarcoma | Disease | GC | ||||||||||||
Juvenile xanthogranuloma | Disease | GC | ||||||||||||
Erdheim-Chester disease | Disease | GC | ||||||||||||
Rosai-Dorfman Disease | Disease | GC | ||||||||||||
ALK-positive histiocytosis | Disease | GC | ||||||||||||
Histiocytic sarcoma | Disease | Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic | GC | |||||||||||
CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) |
|
|
||||||||||||
Reactive B-cell rich lymphoid proliferations that can mimic lymphoma | Disease | GC | ||||||||||||
IgG4-related disease | Disease | GC | ||||||||||||
Unicentric Castleman disease | Disease | GC | ||||||||||||
Idiopathic multicentric Castleman disease | Disease | GC | ||||||||||||
KSHV/HHV8-associated multicentric Castleman disease | Disease | Sudha Arumugam, MD | GC | |||||||||||
B-lymphoblastic leukaemia/lymphoma | Disease | Holli Drendel (HD) | ||||||||||||
B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy | Disease | Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG | HD | |||||||||||
B-lymphoblastic leukaemia/lymphoma with hypodiploidy | Disease | Ashwini Yenamandra PhD FACMG Lisa Smith PhD FACMG Yassmine Akkari PhD FACMG | HD | |||||||||||
B-lymphoblastic leukaemia/lymphoma with iAMP21 | Disease | Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte | HD | |||||||||||
B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion | Disease | Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG | HD | |||||||||||
B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features | Disease | Mark G. Evans, MD, University of California, Irvine Fabiola Quintero-Rivera, MD, University of California, Irvine | HD | |||||||||||
B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement | Disease | Yassmine Akkari Nicolas Millan | HD | |||||||||||
B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion | Disease | Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG Cancer Category/Type B-Lymphoblastic Leukemia/Lymphoma | HD | |||||||||||
B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features | Disease | HD | ||||||||||||
B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion | Disease | Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO | HD | |||||||||||
B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion | Disease | Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO | HD | |||||||||||
B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion | Disease | HD | ||||||||||||
B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations | Disease | HD | ||||||||||||
B-lymphoblastic leukaemia/lymphoma, NOS | Disease | HD | ||||||||||||
Monoclonal B-cell lymphocytosis | Disease | Shivani Golem (SG) | ||||||||||||
Chronic lymphocytic leukaemia/small lymphocytic lymphoma | Disease | Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD | SG | |||||||||||
Hairy cell leukaemia | Disease | *Snehal Patel, MD, PhD | SG | |||||||||||
Splenic marginal zone lymphoma | Disease | *Snehal Patel, MD, PhD | SG | |||||||||||
Splenic diffuse red pulp small B-cell lymphoma | Disease | *Snehal Patel, MD, PhD | SG | |||||||||||
Splenic B-cell lymphoma/leukaemia with prominent nucleoli | Disease | *Snehal Patel, MD, PhD | SG | |||||||||||
Lymphoplasmacytic lymphoma | Disease | Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and *Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI) | SG | |||||||||||
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue | Disease | SG | ||||||||||||
Primary cutaneous marginal zone lymphoma | Disease | SG | ||||||||||||
Nodal marginal zone lymphoma | Disease | Andrew Ly, DO and Shivani Golem, PhD, FACMG | SG | |||||||||||
Paediatric nodal marginal zone lymphoma | Disease | * Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD | SG | |||||||||||
In situ follicular B-cell neoplasm | Disease | Rachel D. Burnside, PhD, MBA, FACMGG | SG | |||||||||||
Follicular lymphoma | Disease | Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital Rachel D. Burnside, PhD, MBA, FACMG, University of Florida | SG | |||||||||||
Paediatric-type follicular lymphoma | Disease | *Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG | SG | |||||||||||
Duodenal-type follicular lymphoma | Disease | SG | ||||||||||||
Primary cutaneous follicle centre lymphoma | Disease | Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG | SG | |||||||||||
In situ mantle cell neoplasm | Disease | Rina Kansal, MD; Versiti Blood Center of Wisconsin | SG | |||||||||||
Mantle cell lymphoma | Disease | * Mahsa Khanlari, MD * Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas | SG | |||||||||||
Leukaemic non-nodal mantle cell lymphoma | Disease | SG | ||||||||||||
Transformations of indolent B-cell lymphomas | Disease | SG | ||||||||||||
Diffuse large B-cell lymphoma, NOS | Disease | Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center | GC | |||||||||||
T-cell/histiocyte-rich large B-cell lymphoma | Disease | GC | ||||||||||||
Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements | Disease | Kate Berry, MBBS, BBus (Hons), Pathology Queensland | GC | |||||||||||
ALK-positive large B-cell lymphoma | Disease | Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | GC | |||||||||||
Large B-cell lymphoma with IRF4 rearrangement | Disease | *Afia Hasnain, MBBS, PhD | GC | |||||||||||
High grade B-cell lymphoma with 11q aberrations | Disease | Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | GC | |||||||||||
Lymphomatoid granulomatosis | Disease | GC | ||||||||||||
EBV-positive diffuse large B-cell lymphoma | Disease | GC | ||||||||||||
Diffuse large B-cell lymphoma associated with chronic inflammation | Disease | GC | ||||||||||||
Fibrin-associated large B-cell lymphoma | Disease | GC | ||||||||||||
Fluid overload-associated large B-cell lymphoma | Disease | GC | ||||||||||||
Plasmablastic lymphoma | Disease | Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | GC | |||||||||||
Primary large B-cell lymphoma of immune-privileged sites | Disease | Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center | GC | |||||||||||
Primary cutaneous diffuse large B-cell lymphoma, leg type | Disease | GC | ||||||||||||
Intravascular large B-cell lymphoma | Disease | Kate Berry, MBBS, BBus (Hons), Pathology Queensland | GC | |||||||||||
Primary mediastinal large B-cell lymphoma | Disease | GC | ||||||||||||
Mediastinal grey zone lymphoma | Disease | GC | ||||||||||||
High-grade B-cell lymphoma, NOS | Disease | Aiko Otsubo, PhD, Indiana University | GC | |||||||||||
Burkitt lymphoma | Disease | Becky Leung, MBBS (Hons), BSc, Pathology Queensland | GC | |||||||||||
Primary effusion lymphoma | Disease | GC | ||||||||||||
KSHV/HHV8-positive diffuse large B-cell lymphoma | Disease | GC | ||||||||||||
KSHV/HHV8-positive germinotropic lymphoproliferative disorder | Disease | GC | ||||||||||||
Hyperplasias arising in immune deficiency/dysregulation | Disease | GC | ||||||||||||
Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation | Disease | Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI) | GC | |||||||||||
EBV-positive mucocutaneous ulcer | Disease | GC | ||||||||||||
Lymphomas arising in immune deficiency / dysregulation | Disease | GC | ||||||||||||
Inborn error of immunity-associated lymphoid proliferations and lymphomas | Disease | GC | ||||||||||||
Classic Hodgkin lymphoma | Disease | Patricia V. Hernandez, M.D., Washington University School of Medicine | GC | |||||||||||
Nodular lymphocyte predominant Hodgkin lymphoma | Disease | GC | ||||||||||||
Cold agglutinin disease | Disease | SG | ||||||||||||
IgM monoclonal gammopathy of undetermined significance | Disease | SG | ||||||||||||
Non-IgM monoclonal gammopathy of undetermined significance | Disease | SG | ||||||||||||
Monoclonal gammopathy of renal significance | Disease | SG | ||||||||||||
Immunoglobulin-related (AL) amyloidosis | Disease | Heather E. Williams, PhD, MS, PgD, ErCLG | SG | |||||||||||
Monoclonal immunoglobulin deposition disease | Disease | Chen Yang, MD, PhD, University of Michigan | SG | |||||||||||
Mu heavy chain disease | Disease | SG | ||||||||||||
Gamma heavy chain disease | Disease | Manisha Brahmbhatt-Sutariya Asst. Professor, Dept. of Pathology and Human Anatomy Technical Supervisor, Clinical Genetics Laboratory Loma Linda University, Medical Center, CA | SG | |||||||||||
Alpha heavy chain disease | Disease | SG | ||||||||||||
Plasmacytoma | Disease | SG | ||||||||||||
Plasma cell myeloma / multiple myeloma | Disease | *Huan Mo, MD, MS *Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas | SG | |||||||||||
Plasma cell neoplasms with associated paraneoplastic syndrome | Disease | Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD | SG | |||||||||||
CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) |
|
|
||||||||||||
Kikuchi-Fujimoto disease | Disease | Sumi Kitahara (SK) | ||||||||||||
Autoimmune lymphoproliferative syndrome | Disease | SK | ||||||||||||
Indolent T-lymphoblastic proliferation | Disease | SK | ||||||||||||
T-lymphoblastic leukaemia / lymphoma, NOS | Disease | HD | ||||||||||||
Early T-precursor lymphoblastic leukaemia / lymphoma | Disease | Fei Yang, MD, FACMG, Kaiser Permanente Northwest | HD | |||||||||||
T-prolymphocytic leukaemia | Disease | SK | ||||||||||||
T-large granular lymphocytic leukaemia | Disease | *Michelle Don, MD, MS | SK | |||||||||||
NK-large granular lymphocytic leukaemia | Disease | Michelle Don, MD | SK | |||||||||||
Adult T-cell leukaemia/lymphoma | Disease | Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center | SK | |||||||||||
Sezary syndrome | Disease | Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | SK | |||||||||||
Aggressive NK-cell leukaemia | Disease | Shanelle De Lancy, MD, Shashirekha Shetty, PhD | SK | |||||||||||
Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder | Disease | SK | ||||||||||||
Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder | Disease | SK | ||||||||||||
Mycosis fungoides | Disease | Jane Scribner, MD and Daynna J. Wolff, PhD | SK | |||||||||||
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis | Disease | SK | ||||||||||||
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma | Disease | Theresa Spivey, MD, Shashirekha Shetty, PhD | SK | |||||||||||
Subcutaneous panniculitis-like T-cell lymphoma | Disease | SK | ||||||||||||
Primary cutaneous gamma/delta T-cell lymphoma | Disease | SK | ||||||||||||
Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma | Disease | SK | ||||||||||||
Primary cutaneous peripheral T-cell lymphoma, NOS | Disease | SK | ||||||||||||
Indolent T-cell lymphoma of the gastrointestinal tract | Disease | Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | SK | |||||||||||
Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract | Disease | SK | ||||||||||||
Enteropathy-associated T-cell lymphoma | Disease | *Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD | SK | |||||||||||
Monomorphic epitheliotropic intestinal T-cell lymphoma | Disease | Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | SK | |||||||||||
Intestinal T-cell lymphoma, NOS | Disease | Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA) | SK | |||||||||||
Hepatosplenic T-cell lymphoma | Disease | *Michelle Don, MD, MS | SK | |||||||||||
ALK-positive anaplastic large cell lymphoma | Disease | SK | ||||||||||||
ALK-negative anaplastic large cell lymphoma | Disease | Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA | SK | |||||||||||
Breast implant-associated anaplastic large cell lymphoma | Disease | Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | SK | |||||||||||
Nodal TFH cell lymphoma, angioimmunoblastic-type | Disease | * Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG | SK | |||||||||||
Nodal TFH cell lymphoma, follicular-type | Disease | SK | ||||||||||||
Nodal TFH cell lymphoma, NOS | Disease | Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD | SK | |||||||||||
Peripheral T-cell lymphoma, NOS | Disease | SK | ||||||||||||
EBV-positive nodal T- and NK-cell lymphoma | Disease | SK | ||||||||||||
Extranodal NK/T-cell lymphoma | Disease | SK | ||||||||||||
Severe mosquito bite allergy | Disease | SK | ||||||||||||
Hydroa vacciniforme lymphoproliferative disorder | Disease | SK | ||||||||||||
Systemic chronic active EBV disease | Disease | SK | ||||||||||||
Systemic EBV-positive T-cell lymphoma of childhood | Disease | *Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA | SK | |||||||||||
CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES) |
|
|
||||||||||||
Follicular dendritic cell sarcoma | Disease | Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG | GC | |||||||||||
EBV-positive inflammatory follicular dendritic cell sarcoma | Disease | GC | ||||||||||||
Fibroblastic reticular cell tumour | Disease | GC | ||||||||||||
Intranodal palisaded myofibroblastoma | Disease | GC | ||||||||||||
Littoral cell angioma | Disease | GC | ||||||||||||
Splenic hamartoma | Disease | GC | ||||||||||||
Sclerosing angiomatoid nodular transformation (SANT) of spleen | Disease | GC | ||||||||||||
CHAPTER 7 (GENETIC TUMOUR SYNDROMES) |
|
|
||||||||||||
Fanconi anaemia | Disease | NA | ||||||||||||
Bloom syndrome | Disease | NA | ||||||||||||
Ataxia-telangiectasia syndrome | Disease | NA | ||||||||||||
RASopathies | Disease | NA |